Adrenomedullin Gene Delivery is Cardio-protective in a Model of Chronic Nitric Oxide Deficiency Combining Pressure Overload, Oxidative Stress and Cardiomyocyte Hypertrophy

Abstract

Background/aims: Chronic inhibition of nitric oxide (NO) synthesis is associated with hypertension, myocardial ischemia, oxidative stress and hypertrophy; expression of the vasodilator peptide, adrenomedullin (AM) and its receptors is augmented in cardiomyocytes, indicating that the myocardial AM system may be activated in response to pressure loading and ischemic insult to serve a counter-regulatory, cardio-protective role. The study examined the hypothesis that oxidative stress and hypertrophic remodeling in NO-deficient cardiomyocytes are attenuated by adenoviral vector-mediated delivery of the human adrenomedullin (hAM) gene in vivo. Methods: The NO synthesis inhibitor, N^G-nitro-L-arginine methyl ester (L-NAME, 15mg · kg^-1 · day^-1) was given to rats for 4 weeks following systemic administration via the tail vein of a single injection of either adenovirus harbouring hAM cDNA under the control of the cytomegalovirus promoter-enhancer (Ad.CMV-hAM-4F2), or for comparison, adenovirus alone (Ad.Null) or saline. Cardiomyocytes were subsequently isolated for assessment of the influence of each intervention on parameters of oxidative stress and hypertrophic remodelling. Results: Cardiomyocyte expression of the transgene persisted for ≧4 weeks following systemic administration of adenoviral vector. In L-NAME treated rats, relative to Ad.Null or saline administration, Ad.CMV-hAM-4F2 (i) reduced augmented cardiomyocyte membrane protein oxidation and mRNA expression of pro-oxidant (p22phox) and anti-oxidant (SOD-3, GPx) genes; (ii) attenuated increased cardiomyocyte width and mRNA expression of hypertrophic (sk-α-actin) and cardio-endocrine (ANP) genes; (iii) did not attenuate hypertension. Conclusions: Adenoviral vector mediated delivery of hAM resulted in attenuation of myocardial oxidative stress and hypertrophic remodelling in the absence of blood pressure reduction in this model of chronic NO-deficiency. These findings are consistent with a direct cardio-protective action in the myocardium of locally-derived hAM which is not dependant on NO generation.

Pregestational type 2 diabetes mellitus induces cardiac hypertrophy in the murine embryo through cardiac remodeling and fibrosis

“…2C and 2D). ADM attenuates hypertrophic remodeling 33 , and maternal T2DM suppressed the expression of ADM (Fig. 2E).…”

(–)-Epicatechin Suppresses Angiotensin II-induced Cardiac Hypertrophy via the Activation of the SP1/SIRT1 Signaling Pathway

“…Cardiac hypertrophy is a major consequence of the heart overload or pathophysiological injury [1]. The typical features of cardiac hypertrophy are reactivation of fetal cardiac genes and increased heart mass and associated changes in the shape of the left ventricle.…”

MicroRNA-22 Downregulation by Atorvastatin in a Mouse Model of Cardiac Hypertrophy: a new Mechanism for Antihypertrophic Intervention

“…The typical features of cardiac hypertrophy are reactivation of fetal genes, reorganization of sarcomere, and enlargement of cardiomyocyte size [1]. Although physiological hypertrophy shows an enhancement of cardiac function, prolonged cardiac hypertrophy will eventually lead to heart failure or sudden death by activating intracellular signaling pathways and transcriptional mediators in cardiac myocytes [2].…”